healthcare · stock-sale · committee-conflict

Rep. Rick Allen Sells Abbott Labs Stock Just Days Before Post-Earnings Surge

The Georgia Republican missed out on a 28% rally after trimming his healthcare holdings to buy semiconductor stocks.

2026-08-21 — Richard W. Allen · ABT

Key facts

Rep. Richard W. Allen (R-Ga.) recently demonstrated the perils of active portfolio management. On July 14, 2026, the Georgia Republican sold between $15,001 and $50,000 of Abbott Laboratories (ABT), a healthcare giant subject to the oversight of the House Energy and Commerce Committee on which he serves.

The timing was less than ideal. Just two days later, on July 16, Abbott reported its second-quarter earnings, raising its full-year guidance and triggering a significant rally. Since Allen's sale at $88.96 per share, Abbott's stock has surged 28.3% to $114.14. By unloading his shares when he did, Allen missed out on thousands of dollars in potential gains.

Under the STOCK Act, members of Congress are required to disclose their financial transactions within 45 days. Allen filed his disclosure on August 18, 2026, 35 days after the trade. Disclosed amounts are reported in ranges rather than exact figures.

Adding a layer of irony, Allen's transaction was part of a same-day multi-asset reshuffle. On the same day he trimmed his Abbott position, he purchased between $1,001 and $15,000 of both Broadcom (AVGO) and Advanced Micro Devices (AMD). While Abbott soared, AMD shares subsequently fell over 11%, compounding the opportunity cost of the rotation.

Corporate insiders at Abbott showed mixed sentiment around the same period. While Director John G. Stratton purchased 2,000 shares in May at $86.82, Executive Vice President Louis H. Morrone capitalized on the post-earnings bump, selling 5,850 shares on August 11 at $109.83.

Our analysis scored the trade 39/100, reflecting that while the timing was highly conspicuous, the trade appears to be part of a systematic trimming of a position Allen has held since 2019 rather than a sudden, policy-driven exit. Nonetheless, the trade highlights the persistent optics issues when members of powerful committees trade heavily regulated sectors.

Sometimes, the market's invisible hand delivers a swift lesson in sector rotation.

Sources

  1. Abbott Q2 2026 Earnings 8-K — SEC EDGAR
  2. Director John G Stratton Form 4 Purchase — SEC EDGAR
  3. EVP Louis H. Morrone Form 4 Sale — SEC EDGAR

All stories · Richard W. Allen · ABT